Table 1.
Baseline characteristics of patients with stage C or D heart failure with non-ischaemic dilated cardiomyopathy but without AF
| Mean+SD/Median and IQRs | All patients (n=192) |
| Age, mean (SD) (years) | 53±14 |
| Male (%) | 140 (72.92%) |
| BMI, mean (SD) (kg/m2) | 26.09±5.18 |
| Hypertension (%) | 78 (41.27%) |
| Diabetes mellitus (%) | 28 (14.81%) |
| CKD (%) | 2 (1.06%) |
| LBBB on EKG (%) | 33 (17.65%) |
| RBBB on EKG (%) | 9 (4.81%) |
| Intraventricular block on EKG (%) | 13 (6.91%) |
| QRS duration mean (SD) (ms) | 124.18±31.62 |
| Alanine aminotransferase (ALT) (U/L) | 33.39±33.63 |
| Aspartate aminotransferase (AST) (U/L) | 28.90±24.46 |
| Creatinine mean (SD) (mmol/L) | 82.53±25.22 |
| Na+ (SD) (mmol/L) | 139.83±2.59 |
| Cl− (SD) (mmol/L) | 102.76±4.60 |
| hs-CRP mean (SD) (mmol/L) | 3.53±5.42 |
| Homocysteine (μmol/L) | 23.43±32.48 |
| White blood cell (G/L) | 6.83±1.83 |
| Haemoglobin (G/L) | 147.76±19.72 |
| Platelets (G/L) | 210.08±64.24 |
| BNP (pg/mL) | 245.50 (129.75–514.25) |
| CMR-LVEDV (mL) | 293±110 |
| CMR-LVESV (mL) | 233±104 |
| CMR-LVEF, (%) | 22.37±9.75 |
| CMR-LVMASS (g) | 150.54±49.02 |
| CMR-RVEDV (mL) | 135±44 |
| CMR-RVESV (mL) | 96±41 |
| CMR-RVEF (%) | 30.35±14.11 |
| CMR-LVpGLS (%) | −6.12±2.78 |
| CMR-LVpGCS (%) | −7.19±2.89 |
| CMR-RVpGCS (%) | −7.71±3.76 |
| CMR-RVpGLS (%) | −10.49±5.16 |
| CMR-LVLGE (%) | 64 (33.51%) |
| Medication | |
| ACEI/ARB/ARNI (%) | 176 (91.57%) |
| Beta-blocker (%) | 184 (95.83%) |
| Spironolactone (%) | 172 (89.58%) |
ACEI, ACE inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BMI, body mass index; BNP, brain natriuretic peptide; CKD, chronic kidney disease; CMR, cardiac magnetic resonance; hs-CRP, high-sensitivity C reactive protein; LBBB, left bundle branch block; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVLGE, left ventricular late gadolinium enhancement; LVMASS, left ventricular mass; LVpGCS, left ventricular peak global circumferential strain; LVpGLS, left ventricular peak global longitudinal strain; RBBB, right bundle branch block; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVESV, right ventricular end-systolic volume; RVpGCS, right ventricular peak global circumferential strain; RVpGLS, right ventricular peak global longitudinal strain.